Ownership and insider activity for Sight Sciences, Inc. (SGHT): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Sight Sciences, Inc. (SGHT) is an ophthalmic medical device firm dedicated to pioneering and bringing to market both surgical and non-surgical innovations aimed at treating various eye diseases. Its product portfolio features the OMNI Surgical System, a therapeutic instrument utilized by eye surgeons to alleviate intraocular pressure in adult glaucoma patients.
Price
| Price | $8.14 |
| Market Cap | $443M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-10 | Rashid Kashif | A-Award | 181,818 | |
| 2026-08-10 | Rashid Kashif | |||
| 2026-07-06 | HAYDEN JEREMY B. | S-Sale | 12,733 | $70K |
| 2026-07-02 | Rodberg James | S-Sale | 6,902 | $37K |
| 2026-07-06 | Badawi David | S-Sale | 7,418 | $41K |
| 2026-07-01 | Taylor Brenton | S-Sale | 2,829 | $15K |
| 2026-07-02 | Bauerlein Alison | S-Sale | 24,184 | $130K |
| 2026-07-01 | Badawi Paul | S-Sale | 28,684 | $155K |
| 2026-06-10 | Encrantz Staffan | P-Purchase | 14,100 | $69K |
| 2026-06-04 | Fountain Tamara | A-Award | 28,261 |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.2M | $21.2M | $61.5M | $260.7M | $185.0M | $138.1M | $120.4M | $92.0M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $1.8M | $4.1M | $5.4M | $8.7M | $15.1M | $14.3M | $10.8M | $9.7M |
| Inventory | $486000 | $2.2M | $2.6M | $3.5M | $6.1M | $7.8M | $6.3M | $7.8M |
| Total Current Assets | $7.2M | $28.0M | $70.6M | $277.0M | $209.7M | $162.9M | $139.8M | $112.7M |
| Property, Plant & Equipment | $868000 | $2.6M | $1.8M | $2.9M | $3.2M | $3.1M | $2.5M | $2.0M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $8.1M | $30.7M | $72.8M | $280.2M | $213.1M | $166.7M | $142.8M | $115.3M |
| Accounts Payable | $1.9M | $2.3M | $2.2M | $3.4M | $2.7M | $1.7M | $1.7M | $1.3M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | $2.2M | 0 | 0 |
| Total Current Liabilities | $2.9M | $7.3M | $9.3M | $13.5M | $17.8M | $12.3M | $15.5M | $11.0M |
| Long-term Debt | $34.2M | $12.9M | $32.0M | $32.7M | $33.3M | $31.7M | $39.4M | $40.3M |
| Total Liabilities | $37.1M | $85.4M | $161.7M | $48.1M | $53.0M | $46.4M | $55.3M | $51.4M |
| Retained Earnings | -$29.5M | -$55.3M | -$90.0M | -$153.0M | -$239.2M | -$294.8M | -$346.3M | -$384.7M |
| Total Equity | -$29.0M | -$54.7M | -$88.8M | $232.1M | $160.1M | $120.2M | $87.5M | $63.9M |
| Total Debt | $34.2M | $13.9M | $32.5M | $34.2M | $35.0M | $35.4M | $40.4M | $40.8M |
| Net Debt | $29.9M | -$7.3M | -$29.0M | -$226.5M | -$150.0M | -$102.7M | -$80.0M | -$51.2M |
| Working Capital | $4.3M | $20.7M | $61.3M | $263.5M | $191.9M | $150.6M | $124.3M | $101.7M |
Financial Health
| Debt / Equity | 0.79 |
| Current Ratio | 4.95 |
Profitability
| Return on Equity | -50.64% |
| Return on Invested Capital | -29.34% |
| Return on Assets | -28.37% |
| Gross Margin | 87.96% |
| Operating Margin | -33.43% |
| Net Margin | -35.69% |
Related companies: CERS · CVRX · LFCR · MASS · OMI · PRQR · QTRX
Explore sector: Healthcare · Medical - Devices
More sections of SGHT: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks